Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
5.335
-0.025 (-0.47%)
Streaming Delayed Price
Updated: 11:31 AM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
September 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
August 15, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
August 13, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
August 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
Business Wire
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
August 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
May 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
April 12, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
February 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
February 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
January 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
November 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
November 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
October 26, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Corporate Update at Investor Day
September 19, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Host Investor Day on September 19, 2023
August 22, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
August 14, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.